Price$26.88-0.63 (-2.27%)
01:30 PM07:45 PM
News · 26 weeks52-50%
2026-04-192026-10-11
Mix2090d
- Insider8(40%)
- Other5(25%)
- SEC Filings3(15%)
- Earnings2(10%)
- Analyst2(10%)
Latest news
25 items- PRProgyny to Present New Menopause Research at The Menopause Society 2026 Annual MeetingNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026. As a leading provider of employer-sponsored menopause care around the globe, Progyny is committed to expanding access to high quality, evidence-based care and demonstrating its impact on women's health outcomes. The research, "Scaling Access to Menopause Care: Real-World Symptom Improvement in an Employer-Sponsored Program," will be presented
- PRProgyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market DynamicsExpecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI Progyny’s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today revealed key insights from the Company’s current annual selling season,
- INSIDEREVP, GC Swartz Allison sold $101,868 worth of shares (3,903 units at $26.10) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 75,816 units (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERChief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,009 units (SEC Form 4) to cover taxes4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERAmendment: Director Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $311,858 worth of shares (11,500 units at $27.12) (SEC Form 4)4/A - Progyny, Inc. (0001551306) (Issuer)
- INSIDERDirector Gordon Kevin K exercised 22,000 shares at a strike of $13.00, covered exercise/tax liability with 10,500 shares and sold $321,358 worth of shares (11,500 units at $27.94) (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- SECSEC Form 144 filed by Progyny Inc.144 - Progyny, Inc. (0001551306) (Subject)
- INSIDERCHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 806,111 units (SEC Form 4) to satisfy tax liability4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDEREVP, GC Swartz Allison covered exercise/tax liability with 1,307 shares, decreasing direct ownership by 2% to 79,719 units (SEC Form 4) (withholding tax)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.66% to 72,453 units (SEC Form 4) (withholding tax)4 - Progyny, Inc. (0001551306) (Issuer)
- PRProgyny, Inc. to Present at the Wells Fargo Healthcare ConferenceNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purcha
- INSIDEREVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares, decreasing direct ownership by 2% to 81,026 units (SEC Form 4) to satisfy withholding tax4 - Progyny, Inc. (0001551306) (Issuer)
- ANALYSTWells Fargo initiated coverage on Progyny with a new price targetWells Fargo initiated coverage of Progyny with a rating of Overweight and set a new price target of $37.00
- PRProgyny, Inc. to Present at the Canaccord Genuity Annual Growth ConferenceNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world
- SECSEC Form 10-Q filed by Progyny Inc.10-Q - Progyny, Inc. (0001551306) (Filer)
- SECProgyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Progyny, Inc. (0001551306) (Filer)
- PRProgyny, Inc. Announces Second Quarter 2026 ResultsReports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders Through the Repurchase of Over 2 Million Shares Under Current Authorization NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2026 ("the second quarter of 2026"), as compared to the three-month period ended June 30, 2025 ("the second quarter of 2025" or "the prior year period"). "The st
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)
- ANALYSTProgyny downgraded by Barclays with a new price targetBarclays downgraded Progyny from Overweight to Equal Weight and set a new price target of $34.00
- PRProgyny, Inc. Announces Details for Its Second Quarter 2026 Results ReportNEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An
- INSIDERChief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERChief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation4 - Progyny, Inc. (0001551306) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDEREVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)4 - Progyny, Inc. (0001551306) (Issuer)
PGNY FAQ
7 questionsWhat does Progyny Inc. do?
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was...Where does PGNY stock trade?
Progyny Inc. (PGNY) is listed on NASDAQ.What sector and industry is PGNY in?
Progyny Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did Progyny Inc. go public?
Progyny Inc. (PGNY) completed its IPO in 2019.What are analysts saying about PGNY?
Progyny Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $3700.00 price target on 2026-08-20. Recent price targets range from $2800.00 to $3700.00.What companies are similar to PGNY?
Notable peers in the same industry include FMS (Fresenius Medical Care AG), DVA (DaVita Inc.), SHC (Sotera Health Company), AGL (agilon health inc.), VMD (Viemed Healthcare Inc.). Compare PGNY side-by-side with any of them on Quantisnow.How can I track PGNY on Quantisnow?
Quantisnow aggregates Progyny Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PGNY to receive live email and push alerts on every new disclosure.